Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01428
|
|||||
| Drug Name |
Pirenzepine
|
|||||
| Synonyms |
Gasteril; Gastrotsepin; Gastrozepin; Pirenzepin; Pirenzepina; Pirenzepinum; Pyrenzepine; Ulcosan; Pirenzepine Gastrozepin; Gastrozepin (TN); L-S 519; Pirenzepina [INN-Spanish]; Pirenzepine (INN); Pirenzepine [INN:BAN]; Pirenzepinum [INN-Latin]; 11-((4-Methyl-1-piperazinyl)acetyl)-5,11-dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one; 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 11-[2-(4-methylpiperazin-1-yl)acetyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one; 5,11-Dihydro-11-((4-methyl-1-piperazinyl)acetyl)-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Peptic ulcer [ICD11: DA61] | Approved | [1] | |||
| Therapeutic Class |
Antiulcer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H21N5O2
|
|||||
| Canonical SMILES |
CN1CCN(CC1)CC(=O)N2C3=CC=CC=C3C(=O)NC4=C2N=CC=C4
|
|||||
| InChI |
InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)
|
|||||
| InChIKey |
RMHMFHUVIITRHF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 28797-61-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 351.4 | Topological Polar Surface Area | 68.8 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
0.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9711
, 5518525
, 7980332
, 8152981
, 11111661
, 11111662
, 11113363
, 11335302
, 11360541
, 11364272
, 11366834
, 11369396
, 11372544
, 11373933
, 11377558
, 11461513
, 11466157
, 11467277
, 11485230
, 11485853
, 11489233
, 11491268
, 11492252
, 11495192
, 14852009
, 26751604
, 29223929
, 46509029
, 47211770
, 47216642
, 47365035
, 47365036
, 47515172
, 47588849
, 47959578
, 47959579
, 48110309
, 48334341
, 48416446
, 49698919
, 50034085
, 50100327
, 50104261
, 50139450
, 50423922
, 57322487
, 81065495
, 81093320
, 85209239
, 85787888
|
|||||
| ChEBI ID |
ChEBI:8247
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (3G0285N20N) | |||||
| 2 | Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.